ID

36098

Descrizione

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK); ODM derived from: https://clinicaltrials.gov/show/NCT02319837

collegamento

https://clinicaltrials.gov/show/NCT02319837

Keywords

versioni (1)
  1. 15/04/19 15/04/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

15 aprile 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Hormone Sensitive Prostate Cancer NCT02319837

Inglese

Eligibility Hormone Sensitive Prostate Cancer NCT02319837

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features;
Descrizione

Adenocarcinoma of prostate Biopsy | Neuroendocrine Differentiation Absent | Signet ring cell Absent | Absence Feature Cells Small

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0007112
UMLS CUI [1,2]
C0005558
UMLS CUI [2,1]
C1709218
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0333727
UMLS CUI [3,2]
C0332197
UMLS CUI [4,1]
C0332197
UMLS CUI [4,2]
C2348519
UMLS CUI [4,3]
C0007634
UMLS CUI [4,4]
C0700321
prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent;
Descrizione

Radical prostatectomy Curative intent Prostate carcinoma | Therapeutic radiology procedure Curative intent Prostate carcinoma | Brachytherapy Curative intent Prostate carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0194810
UMLS CUI [1,2]
C1276305
UMLS CUI [1,3]
C0600139
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C1276305
UMLS CUI [2,3]
C0600139
UMLS CUI [3,1]
C0006098
UMLS CUI [3,2]
C1276305
UMLS CUI [3,3]
C0600139
psa doubling time ≤ 9 months;
Descrizione

PSA Doubling Time

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0138741
UMLS CUI [1,2]
C2986483
screening psa ≥ 2.0 ng/ml for patients who had radical prostatectomy as primary treatment for prostate cancer or ≥ 5.0 ng/ml and greater than or equal to the nadir +
Descrizione

Prostate specific antigen measurement | Radical prostatectomy Prostate carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201544
UMLS CUI [2,1]
C0194810
UMLS CUI [2,2]
C0600139
2 ng/ml for patients who had radiotherapy as primary treatment for prostate cancer;
Descrizione

Therapeutic radiology procedure Prostate carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0600139
serum testosterone ≥ 150 ng/dl (5.2 nmol/l).
Descrizione

Serum testosterone measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0428413
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior or present evidence of distant metastatic disease as assessed by radiographic imaging;
Descrizione

Distant metastasis Radiographic imaging

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1269798
UMLS CUI [1,2]
C0457276
prior hormonal therapy other than neoadjuvant/adjuvant therapy to treat prostate cancer ≤ 36 months in duration and ≥ 9 months before randomization;
Descrizione

Prior Hormone Therapy Prostate carcinoma | Exception Neoadjuvant Therapy | Exception Adjuvant therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514460
UMLS CUI [1,2]
C0600139
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0600558
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0677850
prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide for prostate cancer;
Descrizione

Cytotoxic Chemotherapy Prostate carcinoma | Aminoglutethimide | Ketoconazole | abiraterone acetate | enzalutamide

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C0600139
UMLS CUI [2]
C0002555
UMLS CUI [3]
C0022625
UMLS CUI [4]
C2607886
UMLS CUI [5]
C3496793
prior systemic biologic therapy, including immunotherapy, for prostate cancer;
Descrizione

Biological treatment Systemic Prostate carcinoma | Prior Immunotherapy Prostate carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1531518
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C0600139
UMLS CUI [2,1]
C1514461
UMLS CUI [2,2]
C0600139
major surgery within 4 weeks before randomization;
Descrizione

Major surgery

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0679637
treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks of randomization;
Descrizione

5-alpha Reductase Inhibitors | Finasteride | Dutasteride

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2936788
UMLS CUI [2]
C0060389
UMLS CUI [3]
C0754659
known or suspected brain metastasis or active leptomeningeal disease;
Descrizione

Metastatic malignant neoplasm to brain | Metastatic malignant neoplasm to brain Suspected | Leptomeningeal disease | Leptomeningeal disease Suspected

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C0750491
UMLS CUI [3]
C0751297
UMLS CUI [4,1]
C0751297
UMLS CUI [4,2]
C0750491
history of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence
Descrizione

Invasive cancer Other | Exception Malignant Neoplasms Treated | Exception Recurrence Unlikely

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677898
UMLS CUI [1,2]
C0205394
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0006826
UMLS CUI [2,3]
C1522326
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0034897
UMLS CUI [3,3]
C0750558
Ritorna all'inizio della pagina

Similar models

Eligibility Hormone Sensitive Prostate Cancer NCT02319837

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate Biopsy | Neuroendocrine Differentiation Absent | Signet ring cell Absent | Absence Feature Cells Small
Item
histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features;
boolean
C0007112 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C1709218 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0333727 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0332197 (UMLS CUI [4,1])
C2348519 (UMLS CUI [4,2])
C0007634 (UMLS CUI [4,3])
C0700321 (UMLS CUI [4,4])
Radical prostatectomy Curative intent Prostate carcinoma | Therapeutic radiology procedure Curative intent Prostate carcinoma | Brachytherapy Curative intent Prostate carcinoma
Item
prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent;
boolean
C0194810 (UMLS CUI [1,1])
C1276305 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C1522449 (UMLS CUI [2,1])
C1276305 (UMLS CUI [2,2])
C0600139 (UMLS CUI [2,3])
C0006098 (UMLS CUI [3,1])
C1276305 (UMLS CUI [3,2])
C0600139 (UMLS CUI [3,3])
PSA Doubling Time
Item
psa doubling time ≤ 9 months;
boolean
C0138741 (UMLS CUI [1,1])
C2986483 (UMLS CUI [1,2])
Prostate specific antigen measurement | Radical prostatectomy Prostate carcinoma
Item
screening psa ≥ 2.0 ng/ml for patients who had radical prostatectomy as primary treatment for prostate cancer or ≥ 5.0 ng/ml and greater than or equal to the nadir +
boolean
C0201544 (UMLS CUI [1])
C0194810 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
Therapeutic radiology procedure Prostate carcinoma
Item
2 ng/ml for patients who had radiotherapy as primary treatment for prostate cancer;
boolean
C1522449 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
Serum testosterone measurement
Item
serum testosterone ≥ 150 ng/dl (5.2 nmol/l).
boolean
C0428413 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Distant metastasis Radiographic imaging
Item
prior or present evidence of distant metastatic disease as assessed by radiographic imaging;
boolean
C1269798 (UMLS CUI [1,1])
C0457276 (UMLS CUI [1,2])
Prior Hormone Therapy Prostate carcinoma | Exception Neoadjuvant Therapy | Exception Adjuvant therapy
Item
prior hormonal therapy other than neoadjuvant/adjuvant therapy to treat prostate cancer ≤ 36 months in duration and ≥ 9 months before randomization;
boolean
C1514460 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0677850 (UMLS CUI [3,2])
Cytotoxic Chemotherapy Prostate carcinoma | Aminoglutethimide | Ketoconazole | abiraterone acetate | enzalutamide
Item
prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide for prostate cancer;
boolean
C0677881 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0002555 (UMLS CUI [2])
C0022625 (UMLS CUI [3])
C2607886 (UMLS CUI [4])
C3496793 (UMLS CUI [5])
Biological treatment Systemic Prostate carcinoma | Prior Immunotherapy Prostate carcinoma
Item
prior systemic biologic therapy, including immunotherapy, for prostate cancer;
boolean
C1531518 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C1514461 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
Major surgery
Item
major surgery within 4 weeks before randomization;
boolean
C0679637 (UMLS CUI [1])
5-alpha Reductase Inhibitors | Finasteride | Dutasteride
Item
treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks of randomization;
boolean
C2936788 (UMLS CUI [1])
C0060389 (UMLS CUI [2])
C0754659 (UMLS CUI [3])
Metastatic malignant neoplasm to brain | Metastatic malignant neoplasm to brain Suspected | Leptomeningeal disease | Leptomeningeal disease Suspected
Item
known or suspected brain metastasis or active leptomeningeal disease;
boolean
C0220650 (UMLS CUI [1])
C0220650 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0751297 (UMLS CUI [3])
C0751297 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
Invasive cancer Other | Exception Malignant Neoplasms Treated | Exception Recurrence Unlikely
Item
history of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence
boolean
C0677898 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0034897 (UMLS CUI [3,2])
C0750558 (UMLS CUI [3,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial